Serum salusin-? and salusin-? levels in patients with Behcet's disease

Basit Öğe Kaydı
dc.contributor.authorErden, Ilker
dc.contributor.authorDemir, Betul
dc.contributor.authorUcak, Haydar
dc.contributor.authorCicek, Demet
dc.contributor.authorDertlioglu, Selma Bakar
dc.contributor.authorAydin, Suleyman
dc.date.accessioned2024-04-24T17:18:13Z
dc.date.available2024-04-24T17:18:13Z
dc.date.issued2014
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: Behcet' s disease (BD) is a chronic, relapsing, systemic vasculitis of unknown etiology. There is an increased predisposition to insulin resistance and metabolic syndrome (MetS) in BD patients. Objective: The aim of this study was to determine serum salusin-alpha and salusin-beta levels in BD patients and healthy controls and to investigate their association with MetS. Patients and Methods: Twenty-five BD patients and 25 healthy controls were included in the study. Salusin-alpha and salusin-beta levels were measured in blood samples using ELISA. In addition, BD patients and healthy controls were evaluated in terms of MetS. Results: The mean serum salusin-alpha level in BD patients was significantly lower compared to healthy controls (p = 0.03), whereas the mean serum salusin-beta level in BD patients was significantly higher compared to healthy controls (p = 0.03). The mean serum salusin-alpha level was significantly lower in BD patients with MetS compared to BD patients without MetS (p = 0.04). Conclusions: Serum salusin-a level (an anti-atherogenic molecule) was lower, while serum salusin-beta level (a pro-atherogenic molecule) was higher in BD patients. We consider that the decrease in salusin-alpha and the increase in salusin-beta levels contribute to the development of MetS.en_US
dc.identifier.doi10.1684/ejd.2014.2397
dc.identifier.endpage582en_US
dc.identifier.issn1167-1122
dc.identifier.issn1952-4013
dc.identifier.issue5en_US
dc.identifier.pmid25115151
dc.identifier.scopus2-s2.0-84919338898
dc.identifier.scopusqualityQ3
dc.identifier.startpage577en_US
dc.identifier.urihttps://doi.org/10.1684/ejd.2014.2397
dc.identifier.urihttps://hdl.handle.net/11468/18678
dc.identifier.volume24en_US
dc.identifier.wosWOS:000347867700007
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherJohn Libbey Eurotext Ltden_US
dc.relation.ispartofEuropean Journal of Dermatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBehcet's Diseaseen_US
dc.subjectSalusin-Alphaen_US
dc.subjectSalusin-Betaen_US
dc.subjectMetabolic Syndromeen_US
dc.subjectInsulin Resistanceen_US
dc.titleSerum salusin-? and salusin-? levels in patients with Behcet's diseaseen_US
dc.titleSerum salusin-? and salusin-? levels in patients with Behcet's disease
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu